Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
Saved in:
| Title: | Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025. |
|---|---|
| Authors: | Rose AM; Epiconcept, Paris, France.; These authors contributed equally as first authors.; These authors contributed equally to the writing of the paper., Lucaccioni H; Epiconcept, Paris, France.; These authors contributed equally as first authors., Marsh K; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Kirsebom F; UK Health Security Agency, London, England., Whitaker H; UK Health Security Agency, London, England., Emborg HD; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Bolt Botnen A; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark., O'Doherty MG; Public Health Agency, Belfast, United Kingdom., Pozo F; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain., Hameed SS; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Andrews N; UK Health Security Agency, London, England., Hamilton M; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Trebbien R; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark., Lauenborg Møller K; Data Integration and Analyses, Statens Serum Institut, Copenhagen, Denmark., Marques DF; Epiconcept, Paris, France., Murphy S; Public Health Agency, Belfast, United Kingdom., McQueenie R; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Lopez-Bernal J; UK Health Security Agency, London, England., Cottrell S; Public Health Wales, Cardiff, Wales., Bucholc M; Public Health Agency, Belfast, United Kingdom., Kissling E; Epiconcept, Paris, France.; These authors contributed equally to the writing of the paper. |
| Corporate Authors: | European IVE group; European Influenza Vaccine Effectiveness (IVE) group members are listed under Collaborators., Members of the European IVE group |
| Source: | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2025 Feb; Vol. 30 (7). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39980423 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Rose+AM%22">Rose AM</searchLink>; Epiconcept, Paris, France.; These authors contributed equally as first authors.; These authors contributed equally to the writing of the paper.<br /><searchLink fieldCode="AU" term="%22Lucaccioni+H%22">Lucaccioni H</searchLink>; Epiconcept, Paris, France.; These authors contributed equally as first authors.<br /><searchLink fieldCode="AU" term="%22Marsh+K%22">Marsh K</searchLink>; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kirsebom+F%22">Kirsebom F</searchLink>; UK Health Security Agency, London, England.<br /><searchLink fieldCode="AU" term="%22Whitaker+H%22">Whitaker H</searchLink>; UK Health Security Agency, London, England.<br /><searchLink fieldCode="AU" term="%22Emborg+HD%22">Emborg HD</searchLink>; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Bolt+Botnen+A%22">Bolt Botnen A</searchLink>; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22O'Doherty+MG%22">O'Doherty MG</searchLink>; Public Health Agency, Belfast, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pozo+F%22">Pozo F</searchLink>; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Hameed+SS%22">Hameed SS</searchLink>; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Andrews+N%22">Andrews N</searchLink>; UK Health Security Agency, London, England.<br /><searchLink fieldCode="AU" term="%22Hamilton+M%22">Hamilton M</searchLink>; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Trebbien+R%22">Trebbien R</searchLink>; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Lauenborg+Møller+K%22">Lauenborg Møller K</searchLink>; Data Integration and Analyses, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Marques+DF%22">Marques DF</searchLink>; Epiconcept, Paris, France.<br /><searchLink fieldCode="AU" term="%22Murphy+S%22">Murphy S</searchLink>; Public Health Agency, Belfast, United Kingdom.<br /><searchLink fieldCode="AU" term="%22McQueenie+R%22">McQueenie R</searchLink>; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lopez-Bernal+J%22">Lopez-Bernal J</searchLink>; UK Health Security Agency, London, England.<br /><searchLink fieldCode="AU" term="%22Cottrell+S%22">Cottrell S</searchLink>; Public Health Wales, Cardiff, Wales.<br /><searchLink fieldCode="AU" term="%22Bucholc+M%22">Bucholc M</searchLink>; Public Health Agency, Belfast, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kissling+E%22">Kissling E</searchLink>; Epiconcept, Paris, France.; These authors contributed equally to the writing of the paper. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22European+IVE+group%22">European IVE group</searchLink>; European Influenza Vaccine Effectiveness (IVE) group members are listed under Collaborators.<br /><searchLink fieldCode="CA" term="%22Members+of+the+European+IVE+group%22">Members of the European IVE group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100887452%22">Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</searchLink> [Euro Surveill] 2025 Feb; Vol. 30 (7). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22European+Centre+for+Disease+Prevention+and+Control+%28ECDC%29%22">European Centre for Disease Prevention and Control (ECDC) </searchLink><i>Country of Publication: </i>Sweden <i>NLM ID: </i>100887452 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1560-7917 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221025496X%22">1025496X </searchLink><i>NLM ISO Abbreviation: </i>Euro Surveill <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39980423 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.2807/1560-7917.ES.2025.30.7.2500102 Languages: – Code: eng Text: English Titles: – TitleFull: Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Rose AM – PersonEntity: Name: NameFull: Lucaccioni H – PersonEntity: Name: NameFull: Marsh K – PersonEntity: Name: NameFull: Kirsebom F – PersonEntity: Name: NameFull: Whitaker H – PersonEntity: Name: NameFull: Emborg HD – PersonEntity: Name: NameFull: Bolt Botnen A – PersonEntity: Name: NameFull: O'Doherty MG – PersonEntity: Name: NameFull: Pozo F – PersonEntity: Name: NameFull: Hameed SS – PersonEntity: Name: NameFull: Andrews N – PersonEntity: Name: NameFull: Hamilton M – PersonEntity: Name: NameFull: Trebbien R – PersonEntity: Name: NameFull: Lauenborg Møller K – PersonEntity: Name: NameFull: Marques DF – PersonEntity: Name: NameFull: Murphy S – PersonEntity: Name: NameFull: McQueenie R – PersonEntity: Name: NameFull: Lopez-Bernal J – PersonEntity: Name: NameFull: Cottrell S – PersonEntity: Name: NameFull: Bucholc M – PersonEntity: Name: NameFull: Kissling E IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2025 Feb Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1560-7917 Numbering: – Type: volume Value: 30 – Type: issue Value: 7 Titles: – TitleFull: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin Type: main |
| ResultId | 1 |